The TRAfermin in Neuropathic Diabetic Foot Ulcer Study - Southern Europe The TRANS-South Study

NCT ID: NCT01217463

Last Updated: 2014-08-05

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 201 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-11-30
• Study Completion Date: 2013-02-28

Brief Summary

Trafermin is a recombinant human basic fibroblast growth factor (bFGF; original development code, KCB-1), which is manufactured by genetic engineering using Escherichia coli by Kaken Pharmaceutical Co., Ltd. (Tokyo, Japan). Trafermin 0.01% cutaneous spray product kit consisting of a glass bottle containing lyophilized trafermin, a glass bottle with solvent for solution and a spray part to fit the glass bottle after reconstitution of the final product.

The investigators conduct a multinational, randomized, double-blind, placebo controlled, parallel-group, multicentre study consisting of a placebo run-in phase (2w), a treatment phase (max. 12w) and a follow-up phase (3mo+6mo). The primary objective of the study is to demonstrate a superior wound closure rate of diabetic foot ulcers (DFUs) of neuropathic origin after 12 weeks topical daily application of trafermin 0.01% spray compared with placebo, in addition to best local care (off-loading, dressings). Approximately 210 patients will be randomized and it is planned that this study will be conducted at approximately 30 investigational sites in an estimated 4 countries in Europe (Czech Republic,France,Hungary,Italy,).

Conditions

Diabetic Foot Ulcer of Neuropathic Origin

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Trafermin 0.01% spray

Group Type: ACTIVE_COMPARATOR

Trafermin 0.01% spray

Intervention Type: DRUG

For ulcers with a maximum diameter (longest axis) of less or equal to 6 cm, the daily dose of trafermin 0.01% spray is 5 puffs (30 microgram) sprayed onto the wound surface. If the maximum diameter (longest axis) of the ulcer is \>6 cm, the ulcer should be sprayed in two parts, i.e. 5 puffs (30 microgram) sprayed onto each half of the wound surface

Matching placebo spray

Group Type: PLACEBO_COMPARATOR

Trafermin 0.01% spray

Intervention Type: DRUG

For ulcers with a maximum diameter (longest axis) of less or equal to 6 cm, the daily dose of trafermin 0.01% spray is 5 puffs (30 microgram) sprayed onto the wound surface. If the maximum diameter (longest axis) of the ulcer is \>6 cm, the ulcer should be sprayed in two parts, i.e. 5 puffs (30 microgram) sprayed onto each half of the wound surface

Interventions

Trafermin 0.01% spray

For ulcers with a maximum diameter (longest axis) of less or equal to 6 cm, the daily dose of trafermin 0.01% spray is 5 puffs (30 microgram) sprayed onto the wound surface. If the maximum diameter (longest axis) of the ulcer is \>6 cm, the ulcer should be sprayed in two parts, i.e. 5 puffs (30 microgram) sprayed onto each half of the wound surface

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

Patients who fulfill all of the following criteria are eligible for randomization:

Exclusion Criteria

1. Provide written informed consent to participate.

2. Male or female patients age 18 years or older.

3. Type 1 or 2 diabetes.

4. A single full-thickness DFU that has been present for at least 2 weeks.

5. DFU wound surface area below or equal 34 cm2 on the target foot.

6. No exposure of bone in the target DFU.

7. Neuropathy confirmed by loss of protective sensation to monofilament test (Semmes-Weinstein 5.07 monofilament).

8. No predominant ischemia requiring further exploration or treatment, and confirmed by either:

• ABPI on the target leg ( >0.9;below or equal 1.3) or if ABPI is >1.3 or is not assessable,TBPI on target foot above or equal 0.7, OR
• ABPI on target leg (above or equal 0.7;below or equal 0.9) or if ABPI is >1.3 or is not assessable, TBPI on target foot <0.7, AND a toe blood pressure >40 mmHg

2. Completed the 2-week placebo run-in period during which they were compliant to off-loading and to daily application of placebo spray, without major protocol violation. Compliance with the placebo run-in treatment regimen must be "excellent" or "acceptable"

3. Glycosylated hemoglobin (HbA1c) below or equal 10% (from a blood sample taken during the placebo run-in period).

4. Non-infected target foot DFU of confirmed neuropathic origin with:

• ABPI on the target leg (>0.9;below or equal 1.3) or if ABPI is >1.3 or is not assessable,TBPI on target foot above or equal 0.7, OR
• ABPI on target leg (above or equal 0.7;below or equal 0.9) or if ABPI is >1.3 or is not assessable, TBPI on target foot <0.7, AND a toe blood pressure >40 mmHg

5. Target DFU appropriately debrided (<10% black and at least 50% of red/pink on a colorimetric scale)

6. Target DFU of grade A1 or A2 on the University of Texas Wound Classification System or of Grade 1 or 2 of the Wagner classification

7. DFU surface area above or equal 0.9 cm2 and below or equal 20 cm2 confirmed by the investigator's measurement, and its surface area not decreased by more than 40% compared to the selection value.

Patients who fulfill any of the following criteria are not eligible to be enrolled in the study:

1. Active Charcot foot, or inactive Charcot foot, if the target DFU cannot be properly offloaded.

2. Ulcers of non-neuropathic origin (e.g., rheumatoid, radiation-related, vasculitis-related ulcers).

3. Presence of any foot ulcer (whether or not on the target foot) for which local or systemic antibiotic treatment is required.

4. Evidence of skin cancer within or adjacent to the target ulcer.

5. Any infected ulcers, defined as any problem such as (but not limited to) cellulitis, osteomyelitis, gangrene, or deep tissue infection requiring local or systemic antibiotic therapy.

6. Another wound on the same foot as the target DFU. (i.e. Patients with another wound on the same limb as the target DFU are eligible for the study provided the concomitant wound is not infected and is above the ankle of the target foot).

7. Any known active malignancy that requires general, local, surgical or radiation therapy either ongoing or within the previous 6 months; or patients whose treatment has been suspended for compassionate reasons, or who are not considered as cured from any malignancy.

8. Morbid obesity, defined as body mass index (BMI) above or equal 45kg/m2.

9. Clinically significant medical conditions, in the investigator's opinion, that could impair wound healing (e.g. hepatic impairment, immunocompromised patients).

10. Severe renal failure, defined as requirement for hemodialysis or peritoneal dialysis.

11. Females who are pregnant or breastfeeding, or who are of childbearing potential and not practicing a medically approved method of contraception.

12. Concomitant treatment with high dose oral or parenteral corticosteroids, defined as a daily dose of at least 7.5 mg prednisone or equivalent.

13. Participation in another clinical study within the previous 3 months.

14. Current participation in another clinical study with any drug or device.

15. History of drug or alcohol abuse within the previous year.

16. Concurrent severe psychiatric disease (including severe depressive disorder).

17. Known intolerance to the IMP or to any of its excipients.

18. Known to be uncooperative or noncompliant.

19. Outpatients who are unable to comply with the requirement for daily spray application at home (either application by a family member or by a visiting nurse).

20. Any other condition which, in the opinion of the investigator, would render the patient unsuitable for the study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Olympus Biotech Corporation

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jean-Charles Kerihuel, MD

Role: STUDY_DIRECTOR

VERTICAL

Luc Téot, MD

Role: STUDY_CHAIR

Montpellier University Hospital

Locations

Ostrava- Vitkovice, , Czechia

Prague, , Czechia

Prague, , Czechia

Prague, , Czechia

Prague, , Czechia

Bron, , France

Lisieux, , France

Montpellier, , France

Budapest, , Hungary

Budapest, , Hungary

Budapest, , Hungary

Kisvárda, , Hungary

Sátoraljaújhely, , Hungary

Szeged, , Hungary

Szekszárd, , Hungary

Abbiategrasso, , Italy

Campobasso, , Italy

Milan, , Italy

Montfalcone, , Italy

Padua, , Italy

Paola, , Italy

Pisa, , Italy

Pistoia, , Italy

Rome, , Italy

Countries

Czechia; France; Hungary; Italy

Other Identifiers

2010-021014-33

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

TFM-CL3-001

Identifier Type: -

Identifier Source: org_study_id